Breanne Mackenzie
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$1.3MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $1.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 15, 2023 | NIH | SBIR Phase I The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259K | LUNG THERAPEUTICS INC |
| Sep 15, 2023 | NIH | SBIR Phase I The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259K | Lung Therapeutics, Inc. |
| Sep 15, 2023 | NIH | SBIR Phase I The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259K | LUNG THERAPEUTICS INC |
| Sep 15, 2023 | NIH | SBIR Phase I The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259K | Lung Therapeutics, Inc. |
| Aug 1, 2020 | NIH | SBIR Phase I DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE | $300K | LUNG THERAPEUTICS INC |
| Aug 1, 2020 | NIH | SBIR Phase I DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE | $300K | Lung Therapeutics, Inc. |
| Jul 20, 2020 | NIH | SBIR Phase I DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE | $300K | LUNG THERAPEUTICS INC |
| Jul 20, 2020 | NIH | SBIR Phase I DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE | $300K | Lung Therapeutics, Inc. |
| Aug 1, 2019 | NIH | SBIR Phase I Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis | $225K | LUNG THERAPEUTICS INC |
| Aug 1, 2019 | NIH | SBIR Phase I Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis | $225K | Lung Therapeutics, Inc. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,496
Awards as PI#417
Patents#273
Companies
- Lung Therapeutics, Inc.Linked by awards
- LUNG THERAPEUTICS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.